TROPION-Breast02: First-line Dato-DXd shows superiority over chemotherapy in patients with TNBC ineligible for immunotherapy
Breast Cancer
ESMO 2025
Related content
SABCS 2025
Breast Cancer
TROPION-Breast02: Dato-DXd demonstrates favorable safety compared with chemotherapy in first-line TNBC
ESMO 2025
Breast Cancer
ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors
ESMO 2025
Genitourinary Cancer
TROPION-PanTumor03: Dato-DXd plus rilvegostomig shows promising activity in patients with advanced urothelial cancer
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
ESMO Open
Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV
doi: 10.1016/j.esmoop.2025.106031
Lung, Respiratory and Thoracic Cancer
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
Clin Cancer Res
Pecci F, Li H, Di Federico A, Wu J, Chen H, Gariazzo E, Mantuano F, Garbo E, Aldea M, Santo V, Gibbons D, Tran H, Paoloni F, Rossato de Almeida G, Metro G, De Giglio A, Gelsomino F, Wang X, Tiseo M, Rotow J, Ardizzoni A, Lee JJ, Awad MM, Addeo A, Hong L, Negrao MV, Janne PA, Heymach JV, Zhang J, Ricciuti B, Le X
doi: 10.1158/1078-0432.CCR-25-1735
SABCS 2025
Breast Cancer
ASCENT-03: Frontline sacituzumab govitecan improves QoL versus chemotherapy in patients with metastatic TNBC ineligible for PD-1/PD-L1 inhibitors
Lung, Respiratory and Thoracic Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
Lung, Respiratory and Thoracic Cancer
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC
Lung Cancer
Paz-Ares L, Veillon R, Majem M, Zhou C, Tang KJ, Kim SW, Richardson G, Girard N, Sanborn RE, Mansfield AS, Park K, Schuchard J, Diels J, Sermon J, Bhattacharya A, Lorenzini P, Wortman-Vayn H, Knoblauch RE, Agrawal T, Baig M, Ono A, Sabari JK
doi: 10.1016/j.lungcan.2025.108788
Lung, Respiratory and Thoracic Cancer
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases
Lung Cancer
Frehner L, Schär S, Hayoz S, Petermichl V, Speicher P, I Rothschild S, Mauti LA, König D, Finazzi T, Froesch P, Marini S, Allemann A, Mark M, Janthur WD, Stamatiou A, Metaxas Y, Ermiş E, Wagner F, Früh M, Schmid S
doi: 10.1016/j.lungcan.2025.108813